AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8006126 — intervention group
Group type: COMPARATOR
Intervention: Progesterone supplementation (i.m. progesterone at a daily dose of 25‐50 mg for 14 days)
Number of subjects: 14
Study 2722977 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolong granules with a fat-rich breakfast
Number of subjects: 5
Study 2722977 — intervention group
Group type: EXPERIMENTAL
Intervention: Theodur-G granules with a fat-rich breakfast
Number of subjects: 5
Study 2722977 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolong granules with a standard breakfast
Number of subjects: 5
Study 2722977 — intervention group
Group type: EXPERIMENTAL
Intervention: Theodur-G granules with a standard breakfast
Number of subjects: 5
Study 786908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclophenac sodium (Voltaren)
Number of subjects: 182
Study 786908 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 182
Study 786908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 31198216 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydexa with phenylephrine (experimental group)
Number of subjects: 30
Study 31198216 — intervention group
Group type: COMPARATOR
Intervention: Topical decongestants (control group)
Number of subjects: 30
Study 28844508 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab plus SOC
Number of subjects: 4802
Study 28844508 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 4802
Study 26063066 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-40 g LNSs/d containing milk powder
Number of subjects: 1932
Study 26063066 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 or 40 g milk-free LNSs/d
Number of subjects: 1932
Study 26063066 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 1932
Study 26063066 — intervention group
Group type: EXPERIMENTAL
Intervention: No milk LNS group
Number of subjects: 1932
Study 26063066 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk LNS group
Number of subjects: 1932
Study 22647413 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg SPC
Number of subjects: 0
Study 22647413 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 0
Study 21943257 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 233
Study 21943257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 18572868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of medication with local hyperthermia (CRS-2280E system, anal administration of 1 Qianliean suppository, oral doxazosin 4 mg before bedtime for 2 weeks)
Number of subjects: 76
Study 18572868 — intervention group
Group type: COMPARATOR
Intervention: Simple local hyperthermia
Number of subjects: 76
Study 16624082 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang capsule
Number of subjects: 4860
Study 16624082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4860
Study 12749484 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 20915
Study 12749484 — intervention group
Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 20915
Study 10919423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal-tracheal Combitube 37 Fr SA
Number of subjects: 100
Study 10919423 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 100
Study 8828954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy (IVIG) 2 g/kg body weight every 2 months for 2 years
Number of subjects: 0
Study 8828954 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study 8828954 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor 1 i.u. (transfer factor group)
Number of subjects: 0
Study 8215273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 323
Study 8215273 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 323
Study 2953771 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 53
Study 2953771 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat coronary angioplasty
Number of subjects: 53
Study 29523640 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline WMH volume
Number of subjects: 458
Study 29523640 — intervention group
Group type: EXPERIMENTAL
Intervention: WMH progression
Number of subjects: 458
Study 29523640 — intervention group
Group type: COMPARATOR
Intervention: Highest quartile of baseline WMH volume
Number of subjects: 458
Study 29523640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast progression of WMH
Number of subjects: 458
Study 24317461 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-T FLAIR* MRI technique
Number of subjects: 32
Study 22323352 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training 2 x 45 minutes per week for 3 months
Number of subjects: 96
Study 22323352 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual nutritional advice and group sessions on nutrition for the elderly
Number of subjects: 96
Study 22323352 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutritional and physical intervention
Number of subjects: 96
Study 22323352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 20630294 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper system
Number of subjects: 22
Study 20630294 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoSequence system
Number of subjects: 22
Study 18393054 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment
Number of subjects: 53
Study 15533536 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice plus more extended counseling during and after hospitalization (A + C)
Number of subjects: 2095
Study 15533536 — intervention group
Group type: COMPARATOR
Intervention: Modified usual care (UC)
Number of subjects: 2095
Study 15533536 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (A)
Number of subjects: 2095
Study 12429897 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric muscle contractions (240 repetitions, 30 degrees/s)
Number of subjects: 5
Study 10471565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine (Sdx) and pyrimethamine (Pyr) combinations
Number of subjects: 252
Study 8853530 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 0
Study 8853530 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 8853530 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) as consolidation therapy
Number of subjects: 0
Study 2186651 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg intramuscularly
Number of subjects: 82
Study 2186651 — intervention group
Group type: EXPERIMENTAL
Intervention: nefopam 20 mg intramuscularly
Number of subjects: 82
Study 2186651 — intervention group
Group type: COMPARATOR
Intervention: oral paracetamol as required
Number of subjects: 82
Study 252699 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ten units of regular insulin (U.S.P.) twice daily
Number of subjects: 29
Study 252699 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 31877117 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (GLP-1 analog)
Number of subjects: 0
Study 31764368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (completed 9 simulator-based training modules)
Number of subjects: 24
Study 31764368 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (no training modules)
Number of subjects: 24
Study 31764368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group
Number of subjects: 24
Study 27734550 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency treatment applied to the ramus communicans
Number of subjects: 60
Study 27734550 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (same procedure except radiofrequency treatment)
Number of subjects: 60
Study 26543357 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil supplementation (3 g/day)
Number of subjects: 110
Study 26543357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23601899 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction (RYR)
Number of subjects: 216
Study 23601899 — intervention group
Group type: COMPARATOR
Intervention: Conventional loop reconstruction (CLR)
Number of subjects: 216
Study 21824948 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent intervention group (n = 311)
Number of subjects: 641
Study 21824948 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 330)
Number of subjects: 641
Study 21824948 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent intervention group (n = 311) with impaired glucose tolerance at baseline
Number of subjects: 641
Study 21824948 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent intervention group (n = 311) with baseline hemoglobin A(1c) levels of 5.6% or more
Number of subjects: 641
Study 19853772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar scissors circumcision
Number of subjects: 230
Study 19853772 — intervention group
Group type: COMPARATOR
Intervention: Standard scalpel technique
Number of subjects: 230
Study 16990660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest birth weight (<2500 g)
Number of subjects: 973
Study 16990660 — intervention group
Group type: COMPARATOR
Intervention: Highest birth weight (≥3500 g)
Number of subjects: 973
Study 16990660 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 973
Study 16990660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 973
Study 15589067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/d, n = 22)
Number of subjects: 86
Study 15589067 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (3 x 120 mg/d, n = 25)
Number of subjects: 86
Study 15589067 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg sibutramine/d + 3 x 120 mg orlistat/d, n = 20)
Number of subjects: 86
Study 15589067 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (n = 19)
Number of subjects: 86
Study 11394194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with a balanced amino acid mixture followed by pentagastrin (0.6 microgram/kg)
Number of subjects: 6
Study 11394194 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment with a balanced amino acid mixture followed by normal saline placebo
Number of subjects: 6
Study 11394194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with an amino acid mixture without phenylalanine or tyrosine followed by pentagastrin (0.6 microgram/kg)
Number of subjects: 6
Study 9351695 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise for 50 min at 70% of maximum (N=15)
Number of subjects: 30
Study 9351695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for 50 min at 70% of maximum (N=15)
Number of subjects: 30
Study 9351695 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation for 50 min (N=15)
Number of subjects: 30
Study 9351695 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet rest for 50 min (N=15)
Number of subjects: 30
Study 7899678 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation training for four months (group 1)
Number of subjects: 20
Study 7899678 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control group, group 2)
Number of subjects: 20
Study 3236760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and low-fat dietary regimen
Number of subjects: 11
Study 3236760 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11
Study 29084091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-second isometric exercise protocol (P3)
Number of subjects: 14
Study 29084091 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-second isometric exercise protocol (P6)
Number of subjects: 14
Study 29084091 — intervention group
Group type: COMPARATOR
Intervention: Comparison of P3 and P6
Number of subjects: 14
Study 27207349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 0
Study 25909406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/propofol admixture (ketofol)
Number of subjects: 160
Study 25909406 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 160
Study 23885610 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation therapy (group A)
Number of subjects: 86
Study 23885610 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy alone (group B)
Number of subjects: 86
Study 19806358 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for weight loss (12 months)
Number of subjects: 127
Study 18926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular distension and rehabilitation
Number of subjects: 60
Study 18926581 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 60
Study 16740370 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg tid)
Number of subjects: 88
Study 16740370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (800 mg tid)
Number of subjects: 88
Study 16740370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 14658397 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐MIBG scintigraphy
Number of subjects: 62
Study 14658397 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc interval measurement
Number of subjects: 62
Study 14658397 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 62
Study 11011328 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting
Number of subjects: 0
Study 11011328 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 0
Study 11011328 — intervention group
Group type: COMPARATOR
Intervention: Traditional PTCA
Number of subjects: 0
Study 11011328 — intervention group
Group type: COMPARATOR
Intervention: Contemporary CABG
Number of subjects: 0
Study 8783056 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE+DFDBA (experimental)
Number of subjects: 25
Study 8783056 — intervention group
Group type: COMPARATOR
Intervention: ePTFE alone (control)
Number of subjects: 25
Study 1293261 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg preservative-free morphine
Number of subjects: 42
Study 1293261 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 42
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: ER+ tumours
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: ER+PgR+ tumours
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 or 2 tumours (in ER+ patients)
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 or 2 tumours (in patients with nodal involvement)
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: Better-differentiated (grade 1 and 2) tumours
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: ER+ tumours (in patients with no evidence of axillary nodal involvement)
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological grade
Number of subjects: 400
Study 6315442 — intervention group
Group type: EXPERIMENTAL
Intervention: ER content
Number of subjects: 400
Study 30558805 — intervention group
Group type: EXPERIMENTAL
Intervention: Short forearm splint for two weeks postoperatively
Number of subjects: 39
Study 30558805 — intervention group
Group type: COMPARATOR
Intervention: Conventional bandage with early wrist mobilization
Number of subjects: 39
Study 30558805 — intervention group
Group type: EXPERIMENTAL
Intervention: No splint group
Number of subjects: 39
Study 30558805 — intervention group
Group type: COMPARATOR
Intervention: Splint group
Number of subjects: 39
Study 30558805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 29020373 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) - total target dose: 12 mg/kg for artemether and 60 mg/kg for lumefantrine
Number of subjects: 123
Study 29020373 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) - dosage: 25 mg/kg
Number of subjects: 123
Study 29020373 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 123
Study 29020373 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 123
Study 27159308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension group (overconstrain AP laxity by 2 mm)
Number of subjects: 84
Study 27159308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tension group (restore normal AP laxity)
Number of subjects: 84
Study 27159308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension group
Number of subjects: 84
Study 27159308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tension group
Number of subjects: 84
Study 27159308 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched uninjured participants)
Number of subjects: 84
Study 25280578 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion arm (discussion about the meaning and implication of test results, delivered by a nurse before tests in clinic, plus a pre-test pamphlet)
Number of subjects: 120
Study 25280578 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet arm (pre-test pamphlet alone)
Number of subjects: 120
Study 25280578 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion arm
Number of subjects: 120
Study 25280578 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet arm
Number of subjects: 120
Study 22283238 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol XE
Number of subjects: 60
Study 22283238 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 60
Study 22283238 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 60
Study 21067078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein-viewing device
Number of subjects: 91
Study 21067078 — intervention group
Group type: COMPARATOR
Intervention: Baseline data (control group)
Number of subjects: 91
Study 17884787 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF regimen
Number of subjects: 132
Study 17884787 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF regimen
Number of subjects: 132
Study 17884787 — intervention group
Group type: EXPERIMENTAL
Intervention: NEF regimen
Number of subjects: 132
Study 15172468 — intervention group
Group type: EXPERIMENTAL
Intervention: externally‐irrigated catheter
Number of subjects: 80
Study 15172468 — intervention group
Group type: COMPARATOR
Intervention: internally‐cooled catheter
Number of subjects: 80
Study 15172468 — intervention group
Group type: COMPARATOR
Intervention: single sensor, 8‐mm tip catheter
Number of subjects: 80
Study 15172468 — intervention group
Group type: COMPARATOR
Intervention: double sensor, 8‐mm tip catheter
Number of subjects: 80
Study 11748437 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized IMA (Group I)
Number of subjects: 33
Study 11748437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled IMA (Group II)
Number of subjects: 33
Study 11748437 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiskeletonized IMA (Group III)
Number of subjects: 33
Study 9853926 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenylalanine
Number of subjects: 16
Study 9853926 — intervention group
Group type: COMPARATOR
Intervention: Moderate phenylalanine
Number of subjects: 16
Study 7863813 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (3 million IU/day for 6 days/week)
Number of subjects: 7
Study 7863813 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (25 mg/m2 i.v. weekly)
Number of subjects: 7
Study 2488472 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg i.v. bolus followed by 1.5 mg infused over 90 minutes)
Number of subjects: 9
Study 2488472 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 9
Study 2488472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30334954 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard endotracheal tube secured on the same side as head rotation (Group S, n = 29)
Number of subjects: 58
Study 30334954 — intervention group
Group type: COMPARATOR
Intervention: TaperGuard endotracheal tube secured on the opposite side of head rotation (Group O, n = 29)
Number of subjects: 58
Study 30334954 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard endotracheal tube secured on the same side as head rotation (Group S)
Number of subjects: 58
Study 30334954 — intervention group
Group type: COMPARATOR
Intervention: TaperGuard endotracheal tube secured on the opposite side of head rotation (Group O)
Number of subjects: 58
Study 28797307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessments (EMAs) only
Number of subjects: 400
Study 28797307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Interventions (EMIs) only
Number of subjects: 400
Study 28797307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EMAs + EMIs
Number of subjects: 400
Study 28797307 — intervention group
Group type: COMPARATOR
Intervention: Control condition without EMA or EMI
Number of subjects: 400
Study 28797307 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 400
Study 26641099 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week online mindfulness training in addition to usual care (UC)
Number of subjects: 324
Study 26641099 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 324
Study 23595161 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM-BP treatment (rice diet, walks, yoga, relaxation and stress management)
Number of subjects: 113
Study 23595161 — intervention group
Group type: COMPARATOR
Intervention: DASH+exercise control group (DASH and walks)
Number of subjects: 113